Eidogen-Sertanty and Kalypsys Establish Drug Discovery Collaboration
News Dec 15, 2005
Eidogen-Sertanty, Inc. has announced that they have established collaboration with San Diego-based Kalypsys, Inc, focused on the discovery of small molecules for anti-inflammatory indications.
Under the terms of the collaboration, Eidogen-Sertanty will utilize its DirectDesign™ computational drug discovery platform to design a virtual library of synthetically tractable and drug-like compounds with predicted activity against a target of interest to Kalypsys.
The collaboration builds upon Kalypsys’ existing relationship with Eidogen-Sertanty as a customer of the Target Informatics Platform™ (TIP™).
"The team at Eidogen-Sertanty believes that our expertise in targeted library design will help deliver leads for Kalypsys’ small molecule pipeline," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.
"We are pleased to partner with Eidogen-Sertanty. Their technology appears to have great potential and we look forward to applying it to this research effort," stated Stewart Noble, VP of Chemistry at Kalypsys.
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE